lenalidomide + melphalan + prednisone

Lenalidomide + melphalan + prednisone (commonly referred to as MPR) is a combination of **three oral agents** used primarily for the treatment of multiple myeloma, especially in patients who are not eligible for autologous stem cell transplantation. - **Lenalidomide** is a thalidomide analog and an immunomodulatory agent with antineoplastic, anti-angiogenic, and pro-apoptotic activity. It enhances T-cell and natural killer (NK) cell immunity and inhibits cytokine production. - **Melphalan** is an alkylating agent that crosslinks DNA and RNA, preventing cancer cell replication and causing cell death. - **Prednisone** is a synthetic glucocorticoid with anti-inflammatory and immunosuppressive properties, inducing apoptosis in certain cancer cells. This combination has demonstrated significant efficacy, achieving high rates of partial and complete responses in newly diagnosed multiple myeloma patients. The principal toxicity is hematologic, primarily neutropenia and thrombocytopenia. The regimen avoids the neurotoxicity seen with thalidomide-based combinations but is associated with cumulative myelosupp[2][3][7].

Other names

MPR